Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Working Capital Changes (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Other Working Capital Changes data on record, last reported at $1.6 million in Q3 2025.

  • For Q3 2025, Other Working Capital Changes fell 36.99% year-over-year to $1.6 million; the TTM value through Sep 2025 reached -$46000.0, down 100.08%, while the annual FY2024 figure was $1.6 million, 96.82% down from the prior year.
  • Other Working Capital Changes reached $1.6 million in Q3 2025 per GLUE's latest filing, down from $85.7 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $85.7 million in Q2 2025 and bottomed at -$83.9 million in Q1 2025.
  • Average Other Working Capital Changes over 3 years is $5.0 million, with a median of $773000.0 recorded in 2023.
  • The widest YoY moves for Other Working Capital Changes: up 2364.13% in 2025, down 7789.1% in 2025.
  • A 3-year view of Other Working Capital Changes shows it stood at $50.0 million in 2023, then plummeted by 106.7% to -$3.4 million in 2024, then skyrocketed by 147.52% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were $1.6 million in Q3 2025, $85.7 million in Q2 2025, and -$83.9 million in Q1 2025.